Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market

Allergan plc is an Irish pharmaceutical company that acquires, develops, and markets brand name drugs, and in 2017 generated around 80% net sales from the U.S. healthcare system. Allergan plc was formed in February 2015 when Irish–registered Actavis plc acquired U.S.–registered Allergan, Inc., and assumed the Allergan name.

Major players in the global drugs for benign prostatic hypertrophy market are Allergan PLC, Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC.

The drugs for benign prostatic hypertrophy market consists of sales of benign prostatic hypertrophy drugs to treat enlarged prostate glands. Benign Prostatic Hypertrophy is commonly seen in men older than age 50.

Read More On The Global Drugs For Benign Prostatic Hypertrophy Market Report At

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

The global drugs for benign prostatic hypertrophy market was valued at about $4 billion in 2018 and is expected to grow to around $6 billion at a growth rate of around 9% through 2022.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2018, followed by Europe and Asia Pacific. This region is expected to remain the largest during the next five years. The drugs for benign prostatic hypertrophy market in Asia Pacific is forecasted to register the highest growth rate during 2018-2023.

Request A Sample Of The Drugs For Benign Prostatic Hypertrophy Market Report At

https://www.thebusinessresearchcompany.com/sample.aspx?id=2594&type=smp

Combination drugs are increasingly being used in the treatment of benign prostatic hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of benign prostatic hypertrophy.

The drugs for benign prostatic hypertrophy market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast growth by geography.

Leave a Reply

Your email address will not be published. Required fields are marked *